Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Regadenoson
Drug ID BADD_D01921
Description Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Indications and Usage Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)
Marketing Status approved; investigational
ATC Code C01EB21
DrugBank ID DB06213
KEGG ID D05711
MeSH ID C430916
PubChem ID 219024
TTD Drug ID D0XE1C
NDC Product Code 55150-443; 0409-1401; 76329-3321; 42973-229; 76055-0024; 60505-6116; 72611-874; 59285-029; 69766-103; 68083-175; 16729-477; 71288-201; 0641-6253; 65129-1331; 43598-616; 0469-6501; 62147-0220; 36000-364
UNII 2XLN4Y044H
Synonyms regadenoson | Lexiscan | CVT 3146 | CVT3146 | CVT-3146
Chemical Information
Molecular Formula C15H18N8O5
CAS Registry Number 313348-27-5
SMILES CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Infusion site erythema08.02.05.008; 23.03.06.016; 12.07.05.0090.000288%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.000228%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Cardiac flutter02.03.02.012--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling12.07.03.018; 08.02.03.0170.001582%Not Available
Infusion site pain12.07.05.002; 08.02.05.0140.001911%Not Available
Infusion site swelling12.07.05.003; 08.02.05.0020.000863%Not Available
Electrocardiogram PR prolongation13.14.05.012--Not Available
Injection site discomfort12.07.03.019; 08.02.03.0180.001006%Not Available
Hypoaesthesia oral07.05.05.003; 17.02.06.0210.000474%Not Available
Vasodilation procedure25.03.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Abdominal symptom07.01.06.0070.000085%Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Limb discomfort15.03.04.0140.000414%Not Available
Ischaemia24.04.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Renal impairment20.01.03.010--Not Available
Infusion site extravasation12.07.05.008; 08.02.05.0070.006225%
Supraventricular tachyarrhythmia02.03.03.014--Not Available
Bronchial hyperreactivity22.03.01.016--Not Available
Complication associated with device08.07.01.0110.000575%Not Available
Anal incontinence17.05.01.021; 07.01.06.0290.000846%
Psychogenic seizure17.12.03.042; 19.24.01.0070.000085%Not Available
Seizure like phenomena17.12.03.0300.000296%Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages